Yellow Fever Market

Market Overview:

The yellow fever market reached a value of USD 397.4 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 643.4 Million by ​2035​, exhibiting a growth rate (CAGR) of 4.54% during ​2025-2035​.

The yellow fever market has been comprehensively analyzed in IMARC's new report titled "Yellow Fever Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ​2025-2035​". Yellow fever is an epidemic-prone, vaccine-preventable disease transmitted to humans through the bites of infected mosquitoes. The condition has an incubation period of three to six days. Many individuals do not experience symptoms. Common indications include fever, muscle soreness, headache, loss of appetite, nausea, and vomiting. In most cases, symptoms resolve within 3 to 4 days. A small percentage of patients experience a second, more hazardous phase within 24 hours of recovering from their original symptoms. High fever returns and multiple body systems are impacted, most notably the liver and kidneys. During this stage, persons are likely to experience jaundice (yellowing of the skin and eyes), dark urine, and abdominal pain with vomiting. Bleeding can occur from the stomach, eyes, nose, or mouth. Diagnosing yellow fever commonly involves a comprehensive clinical evaluation, travel history, and laboratory tests. The healthcare provider may also perform serological tests, such as ELISA (enzyme-linked immunosorbent assay) to detect viral antibodies in the blood, indicating past or current infection.

The escalating prevalence of mosquito-borne viral disease, in which a virus is transmitted to humans by the bites of infected Aedes and Haemagogus mosquitoes, is primarily driving the yellow fever market. In addition to this, the inflating utilization of oral rehydration therapy that contains sodium, potassium, and glucose for maintaining proper hydration and bodily functions, is also creating a positive outlook for the market. Moreover, the widespread adoption of hemodialysis on account of its numerous advantages, such as reduced uremia, stabilized acid-base levels, and improved overall metabolic balance, is further bolstering the market growth. Apart from this, the rising usage of plasma transfusions, since they help manage disease-induced coagulopathy by restoring clotting factors lost due to liver failure, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of pathogen inactivation technologies, such as Theraflex MB – Plasma (methylene blue) and Theraflex UV-Platelets (ultraviolet C light), to inactivate yellow fever virus in plasma and platelet concentrates, is expected to drive the yellow fever market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the yellow fever market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for yellow fever and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the yellow fever market in any manner.

Drugs:

YF-VAX is a live, attenuated yellow fever vaccine, which contains a weakened (attenuated) version of the virus (the 17D-204 strain). Following vaccination, the attenuated virus replicates locally, activating the immune system in a manner similar to a genuine infection, but without causing disease. This stimulation induces the development of neutralizing antibodies, which are proteins that detect and neutralize the yellow fever virus, preventing it from infecting cells and causing sickness.

Stamaril (17D-YFV), developed by Sanofi, is a live-attenuated yellow fever vaccine derived from the 17D strain of the yellow fever virus. It stimulates the immune system by infecting cells with a weakened virus, triggering innate and adaptive immune responses. This induces neutralizing antibodies (anti-YFV IgG) and memory T cells, providing long-term immunity against yellow fever. A single dose offers lifelong protection, preventing severe infection and complications.

Time Period of the Study

• Base Year: 2024
• Historical Period: ​2019-2024​
• Market Forecast: ​2025-2035​

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the yellow fever market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the yellow fever market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current yellow fever marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the yellow fever market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the yellow fever market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the yellow fever market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of yellow fever across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of yellow fever by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of yellow fever by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with yellow fever across the seven major markets?
• What is the size of the yellow fever patient pool (​2019-2024​) across the seven major markets?
• What would be the forecasted patient pool (​2025-2035​) across the seven major markets?
• What are the key factors driving the epidemiological trend of yellow fever?
• What will be the growth rate of patients across the seven major markets?

Yellow Fever: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for yellow fever drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the yellow fever market?
• What are the key regulatory events related to the yellow fever market?
• What is the structure of clinical trial landscape by status related to the yellow fever market?
• What is the structure of clinical trial landscape by phase related to the yellow fever market?
• What is the structure of clinical trial landscape by route of administration related to the yellow fever market?